Literature DB >> 26937143

Improved prescription of taohechengqi-tang alleviates D-galactosamine acute liver failure in rats.

Yang Zhang1, Jian-Xing Luo1, Xiao-Yu Hu1, Fang Yang1, Sen Zhong1, Wu Lin1.   

Abstract

AIM: To investigate the hepatoprotective effect of improved prescription of Taohechengqi-tang (IPTT) against acute liver failure (ALF) in rats.
METHODS: Seventy specific pathogen free male Wistar rats were randomly divided into four groups: control group (normal rats, n = 10), ALF group (ALF model, n = 20), Stronger Neo-Minophagen C (SNMC) group (ALF model + SNMC, n = 20), and IPTT group (ALF model + IPTT, n = 20). The ALF model group was administered an intraperitoneal injection of D-galactosamine (1.4 g/kg), and the control group received normal saline intraperitoneally. The SNMC and IPTT groups were treated with SMMC (15.6 mg/kg) or IPTT (28.6 g/kg) by gavage at 24 h intervals, and the ALF and control groups were treated with normal saline. At 36 h after injection, serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, and cholinesterase and prothrombin time were determined, and liver histopathological scores were observed by microscopy after hematoxylin and eosin staining. mRNA expression of high mobility group box (HMGB) 1, toll-like receptor (TLR) 4, nuclear factor kappa B (NF-κB) and caspase-3 were analyzed via fluorescence quantitative reverse transcriptase polymerase chain reaction. Proliferating cell nuclear antigen (PCNA) immunohistochemistry in liver tissue was also performed.
RESULTS: D-galactosamine notably decreased the biochemical and coagulation profiles in serum. IPTT not only improved liver function and histopathology but also normalized the gene expression levels in liver tissue. Compared with the model group, in the IPTT and SNMC groups, HMGB1 mRNA/β-actin (0.06 ± 0.03, 0.11 ± 0.04 vs 0.25 ± 0.04, P < 0.05); TLR4 mRNA/β-actin (0.07 ± 0.02, 0.22 ± 0.08 vs 0.41 ± 0.22, P < 0.05); NF-κB mRNA/β-actin (0.74 ± 0.41, 1.78 ± 0.64 vs 2.68 ± 1.35, P < 0.05); and caspase-3 mRNA/β-actin levels were all significantly reduced (1.61 ± 0.45, 2.57 ± 1.04 vs 3.41 ± 0.85, P < 0.05). The gene expression levels were significantly lower in the IPTT group than in the SNMC group (P < 0.05). Compared with the model group, the PCNA expression in liver tissue was significantly enhanced in the IPTT and SNMC groups (36.34 ± 4.91, 25.57 ± 2.94 vs 17.55 ± 2.40, P < 0.05).
CONCLUSION: IPTT attenuates inflammation in ALF via inhibition of HMGB1 production, which may contribute to limited liver regeneration.

Entities:  

Keywords:  Acute liver failure; High mobility group box 1; Inflammation; Taohechengqi-tang; Traditional Chinese medicine

Mesh:

Substances:

Year:  2016        PMID: 26937143      PMCID: PMC4768201          DOI: 10.3748/wjg.v22.i8.2558

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

2.  [Consensus on the clinical significance and evaluation of common liver biochemistry tests].

Authors:  Ji-dong Jia; Liu-fang Cheng
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2010-05

3.  [A prospective cohort study on the influence of high doses of herbs for clearing heat and resolving stasis on survival rates in patients with hepatitis B-related acute-on-chronic liver failure].

Authors:  Xiao-Yu Hu; Yang Zhang; Guo Chen; Sen Zhong; Xin-Jian Fan
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2012-02

4.  [Effects of supplemented taohe chengqi decoction in treating insulin resistance in rats with non-insulin dependent diabetes mellitus].

Authors:  M Q Xiong; A Z Lin; Z Z Zhu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1997-03

5.  Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States.

Authors:  N H Urrunaga; V P Rachakonda; L S Magder; A L Mindikoglu
Journal:  Transplant Proc       Date:  2014 Jan-Feb       Impact factor: 1.066

6.  Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway.

Authors:  Sainan Zhang; Naibin Yang; Shunlan Ni; Wenyuan Li; Lanman Xu; Peihong Dong; Mingqin Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Protective effect of melittin on inflammation and apoptosis in acute liver failure.

Authors:  Ji-Hyun Park; Kyung-Hyun Kim; Woo-Ram Lee; Sang-Mi Han; Kwan-Kyu Park
Journal:  Apoptosis       Date:  2012-01       Impact factor: 4.677

8.  [Preventive and therapeutic effects of extract from Rheum palmatum on hepatic encephalopathy in rats with acute liver failure].

Authors:  Qiuju Zhang; Huijuan Cheng; Chengyong Wang; Changwei Zhang; Jun Wang
Journal:  Zhong Yao Cai       Date:  2002-08

Review 9.  Acute-on chronic liver failure.

Authors:  Rajiv Jalan; Pere Gines; Jody C Olson; Rajeshwar P Mookerjee; Richard Moreau; Guadalupe Garcia-Tsao; Vicente Arroyo; Patrick S Kamath
Journal:  J Hepatol       Date:  2012-06-28       Impact factor: 25.083

10.  RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB.

Authors:  Guellue Cataldegirmen; Shan Zeng; Nikki Feirt; Nikalesh Ippagunta; Hao Dun; Wu Qu; Yan Lu; Ling Ling Rong; Marion A Hofmann; Thomas Kislinger; Sophia I Pachydaki; Daniel G Jenkins; Alan Weinberg; Jay Lefkowitch; Xavier Rogiers; Shi Fang Yan; Ann Marie Schmidt; Jean C Emond
Journal:  J Exp Med       Date:  2005-02-07       Impact factor: 14.307

View more
  2 in total

1.  Chlorella sp. Protective Effect on Acetaminophen-Induced Liver Toxicity in ICR Mice.

Authors:  Jia-Ping Wu
Journal:  Int J Prev Med       Date:  2020-07-22

2.  Anticolon Cancer Targets and Molecular Mechanisms of Tao-He-Cheng-Qi Formula.

Authors:  Zexin Zhang; Siqi Lin; Zifeng Liu; Jun Han; Jing Li; Yi Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-18       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.